APG Asset Management US Inc. Acquires Shares of 4,800 Hologic, Inc. (NASDAQ:HOLX)

APG Asset Management US Inc. acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 4,800 shares of the medical equipment provider’s stock, valued at approximately $346,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Norges Bank bought a new position in shares of Hologic during the fourth quarter valued at approximately $133,414,000. Boston Partners raised its holdings in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Hologic by 16.4% during the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock valued at $293,434,000 after acquiring an additional 572,187 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after acquiring an additional 544,889 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Hologic during the fourth quarter valued at approximately $27,007,000. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent analyst reports. Wolfe Research started coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Citigroup decreased their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Finally, Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Trading Up 1.5 %

Shares of NASDAQ:HOLX opened at $59.31 on Thursday. The stock has a market capitalization of $13.31 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock’s 50-day simple moving average is $63.03 and its two-hundred day simple moving average is $71.87. Hologic, Inc. has a 52-week low of $57.38 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.